دورية أكاديمية
أعرض في EDS

Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines.

التفاصيل البيبلوغرافية
العنوان: Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines.
المؤلفون: Mygland L; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway.; Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317 Oslo, Norway., Brinch SA; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway.; Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317 Oslo, Norway., Strand MF; School of Health Sciences, Kristiania University College, P.O. Box 1190 Sentrum, 0107 Oslo, Norway., Olsen PA; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway.; Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317 Oslo, Norway., Aizenshtadt A; Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317 Oslo, Norway., Lund K; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway., Solberg NT; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway., Lycke M; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway., Thorvaldsen TE; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, 0379 Oslo, Norway., Espada S; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway.; Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317 Oslo, Norway., Misaghian D; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway., Page CM; Center for Fertility and Health, Norwegian Institute of Public Health, P.O. Box 222 Skøyen, 0213 Oslo, Norway.; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, P.O. Box 4950 Nydalen, 0424 Oslo, Norway., Agafonov O; Bioinformatics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Ullernchausseen 70, 0379 Oslo, Norway., Nygård S; Department of Informatics, University of Oslo, P.O. box 080 Blindern, 0316 Oslo, Norway., Chi NW; Endocrine Service, VA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161, USA., Lin E; Department of Discovery Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Tan J; Department of Discovery Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Yu Y; Department of Discovery Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Costa M; Department of Discovery Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Krauss S; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway.; Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317 Oslo, Norway., Waaler J; Department of Immunology and Transfusion Medicine, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway.; Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317 Oslo, Norway.
المصدر: IScience [iScience] 2021 Jul 01; Vol. 24 (7), pp. 102807. Date of Electronic Publication: 2021 Jul 01 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, [2018]-
مستخلص: Small-molecule tankyrase 1 and tankyrase 2 (TNKS1/2) inhibitors are effective antitumor agents in selected tumor cell lines and mouse models. Here, we characterized the response signatures and the in-depth mechanisms for the antiproliferative effect of tankyrase inhibition (TNKSi). The TNKS1/2-specific inhibitor G007-LK was used to screen 537 human tumor cell lines and a panel of particularly TNKSi-sensitive tumor cell lines was identified. Transcriptome, proteome, and bioinformatic analyses revealed the overall TNKSi-induced response signatures in the selected panel. TNKSi-mediated inhibition of wingless-type mammary tumor virus integration site/β-catenin, yes-associated protein 1 (YAP), and phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT signaling was validated and correlated with lost expression of the key oncogene MYC and impaired cell growth. Moreover, we show that TNKSi induces accumulation of TNKS1/2-containing β - catenin degradasomes functioning as core complexes interacting with YAP and angiomotin proteins during attenuation of YAP signaling. These findings provide a contextual and mechanistic framework for using TNKSi in anticancer treatment that warrants further comprehensive preclinical and clinical evaluations.
(© 2021 The Authors.)
References: Nat Cell Biol. 2011 May;13(5):623-9. (PMID: 21478859)
Nature. 2015 Apr 16;520(7547):307-11. (PMID: 25877200)
Cancer Res. 2011 Jan 1;71(1):197-205. (PMID: 21199802)
Nat Rev Mol Cell Biol. 2019 Apr;20(4):199-210. (PMID: 30824861)
Eur J Med Chem. 2017 Dec 15;142:506-522. (PMID: 29107427)
J Biol Chem. 2016 Jul 15;291(29):15256-66. (PMID: 27231341)
Nature. 2016 May 18;533(7603):333-7. (PMID: 27193678)
Annu Rev Pathol. 2011;6:479-507. (PMID: 21090969)
Genes Dev. 2015 Jan 15;29(2):157-70. (PMID: 25547115)
Mol Cancer Res. 2018 Mar;16(3):543-553. (PMID: 29222171)
J Med Chem. 2020 Jul 9;63(13):6834-6846. (PMID: 32511917)
Cancer Lett. 2018 Feb 1;414:1-15. (PMID: 29126913)
Cancer Res. 2014 Jun 15;74(12):3294-305. (PMID: 24747911)
Cancer Sci. 2018 Dec;109(12):4003-4014. (PMID: 30238564)
Genome Res. 2011 Dec;21(12):2213-23. (PMID: 21903743)
Cell. 2014 Jul 3;158(1):157-70. (PMID: 24976009)
Cancers (Basel). 2020 Jun 19;12(6):. (PMID: 32575464)
Signal Transduct Target Ther. 2018 Feb 23;3:5. (PMID: 29527331)
J Biol Chem. 2002 Apr 19;277(16):14116-26. (PMID: 11854288)
Cancer Discov. 2019 Oct;9(10):1358-1371. (PMID: 31337618)
Cell. 2018 Apr 5;173(2):371-385.e18. (PMID: 29625053)
Nucleic Acids Res. 2002 Jan 1;30(1):207-10. (PMID: 11752295)
Biochem J. 2014 Apr 15;459(2):275-87. (PMID: 24467442)
Bioinformatics. 2016 Oct 1;32(19):3012-4. (PMID: 27288499)
J Med Chem. 2013 Aug 22;56(16):6495-511. (PMID: 23844574)
Mol Cell. 2016 Aug 4;63(3):498-513. (PMID: 27494558)
F1000Res. 2018 Aug 31;7:. (PMID: 30228872)
Nature. 2009 Oct 1;461(7264):614-20. (PMID: 19759537)
Commun Biol. 2020 Apr 24;3(1):196. (PMID: 32332858)
J Med Chem. 2013 Apr 11;56(7):3012-23. (PMID: 23473363)
Sci Rep. 2019 Dec 13;9(1):19130. (PMID: 31836723)
Mol Cell Proteomics. 2020 Dec;19(12):2015-2030. (PMID: 32958691)
Nat Rev Cancer. 2015 Oct;15(10):593-607. (PMID: 26383138)
Mol Cell Biol. 2018 Oct 29;38(22):. (PMID: 30181396)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
Oncotarget. 2016 May 17;7(20):28765-82. (PMID: 27144834)
Nucleic Acids Res. 2019 Jan 8;47(D1):D917-D922. (PMID: 30496479)
PLoS One. 2011;6(7):e22595. (PMID: 21799911)
Toxicol Pathol. 2016 Feb;44(2):267-78. (PMID: 26692561)
Oncol Lett. 2018 Dec;16(6):6895-6902. (PMID: 30546421)
J Proteome Res. 2011 Apr 1;10(4):1794-805. (PMID: 21254760)
Science. 1998 Nov 20;282(5393):1484-7. (PMID: 9822378)
Diabetologia. 2016 Mar;59(3):582-91. (PMID: 26631215)
Exp Cell Res. 2020 May 1;390(1):111935. (PMID: 32151493)
Cancer Res. 2012 Jun 1;72(11):2822-32. (PMID: 22440753)
Cell Rep. 2015 Oct 20;13(3):524-532. (PMID: 26456820)
Dev Cell. 2010 Oct 19;19(4):507-20. (PMID: 20951343)
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450. (PMID: 30395289)
J Med Chem. 2013 Jun 13;56(11):4320-42. (PMID: 23701517)
PLoS One. 2017 Jan 20;12(1):e0170508. (PMID: 28107521)
Curr Pharm Des. 2014;20(41):6472-88. (PMID: 24975604)
Nat Commun. 2018 Nov 9;9(1):4728. (PMID: 30413706)
Mol Cancer Ther. 2017 Apr;16(4):752-762. (PMID: 28179481)
Bone. 2018 Jan;106:156-166. (PMID: 29055830)
Cancer Res. 2012 Jul 1;72(13):3119-24. (PMID: 22706201)
Clin Transl Oncol. 2018 Jul;20(7):827-836. (PMID: 29230693)
Nat Commun. 2017 Dec 20;8(1):2214. (PMID: 29263426)
EMBO J. 2012 Jun 13;31(12):2714-36. (PMID: 22617422)
Mol Cancer Res. 2015 Nov;13(11):1487-501. (PMID: 26124443)
Nucleic Acids Res. 2015 Dec 2;43(21):e140. (PMID: 26184878)
J Med Chem. 2017 Dec 28;60(24):10013-10025. (PMID: 29155568)
Cancer Res. 2013 May 15;73(10):3132-44. (PMID: 23539443)
Clin Cancer Res. 2016 Feb 1;22(3):644-56. (PMID: 26224873)
Cell. 2018 Apr 5;173(2):321-337.e10. (PMID: 29625050)
Oncogenesis. 2016 Apr 18;5:e220. (PMID: 27089143)
Science. 1998 Sep 4;281(5382):1509-12. (PMID: 9727977)
Cells. 2019 Jun 17;8(6):. (PMID: 31212916)
Nat Commun. 2019 Sep 25;10(1):4363. (PMID: 31554794)
ACS Med Chem Lett. 2015 Jan 13;6(3):254-9. (PMID: 25815142)
PLoS Biol. 2003 Oct;1(1):E10. (PMID: 14551908)
J Biol Chem. 2004 Sep 24;279(39):40255-8. (PMID: 15304487)
Cell. 2017 Jun 1;169(6):985-999. (PMID: 28575679)
Int J Obes (Lond). 2020 Aug;44(8):1691-1702. (PMID: 32317752)
فهرسة مساهمة: Keywords: Cancer; Proteomics; Transcriptomics
تواريخ الأحداث: Date Created: 20210802 Latest Revision: 20210803
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC8313754
DOI: 10.1016/j.isci.2021.102807
PMID: 34337362
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-0042
DOI:10.1016/j.isci.2021.102807